The chaperone protein GRP78 released from MPN cells increases the expression of lysyl oxidase in a human stromal cell line.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
11 2023
Historique:
received: 04 03 2023
revised: 30 08 2023
accepted: 18 09 2023
medline: 3 11 2023
pubmed: 28 9 2023
entrez: 27 9 2023
Statut: ppublish

Résumé

Impaired function of the endoplasmic stress (ER) response causes numerous pathological conditions, including tissue fibrosis. In the present study, we aimed to determine the pathological role of ER stress response systems in myeloproliferative neoplasms (MPNs). We found increased expression of the chaperone protein glucose-regulated protein (GRP) 78, a central regulator of ER stress, in megakaryocytes from primary myelofibrosis or postessential thrombocythemia myelofibrosis patients. GRP78 was overexpressed in JAK2V617F-harboring cell lines; however, inhibitors of ER stress did not affect the expression levels of GRP78. In contrast, ruxolitinib, a well-known inhibitor of JAK2V617F, clearly blocked GRP78 expression in these cells through downregulation of transcription factor 4 (ATF4). Interestingly, GRP78 was secreted from HEL and SET-2 cells into culture media. Coculture of these cells with HS-5 cells, a human bone marrow stroma-derived cell line, induced enhanced expression of lysyl oxidase (LOX), which mediates cross-linking of collagen fibers and induces tissue fibrosis, in HS-5 cells. An anti-GRP78 neutralizing antibody abrogated LOX elevation; in contrast, recombinant GRP78 protein induced LOX protein expression in HS-5 cells. Our observations suggest that the oncogenic protein JAK2V617F induces overexpression and release of GRP78, which may induce a fibrotic phenotype in surrounding bone marrow stromal cells.

Identifiants

pubmed: 37757654
pii: S0145-2126(23)00654-9
doi: 10.1016/j.leukres.2023.107389
pii:
doi:

Substances chimiques

Endoplasmic Reticulum Chaperone BiP 0
Heat-Shock Proteins 0
Protein-Lysine 6-Oxidase EC 1.4.3.13
HSPA5 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107389

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Auteurs

Kei Nakajima (K)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Megumi Suzuki (M)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Ichiro Kawashima (I)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Megumi Koshiisi (M)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Takuma Kumagai (T)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Takeo Yamamoto (T)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Masaru Tanaka (M)

Department of Hematology/Oncology, University of Yamanashi, Japan.

Keita Kirito (K)

Department of Hematology/Oncology, University of Yamanashi, Japan. Electronic address: kirito@yamanashi.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH